Abstract 68P
Background
Glioblastomas are grade IV gliomas of the central nervous system associated with a median survival rate of less than 15 months. Therefore, research has been focused on better understanding the role of the tumor immune microenvironment, specifically macrophages (tissue-resident and monocyte-derived), which make up to 30% of the tumour. Using imaging mass cytometry, we have demonstrated that long-term survival in glioblastoma is associated with an accumulation of a rare subset of MPO+ monocyte-derived macrophages (MDM) within tumors, which appeared to originate from a shift in monocytosis. Transcriptomics analyses revealed that these macrophages exhibited heightened effector functions, potentially explaining their association with prolonged survival. This raises the question of whether monocyte developmental trajectories can be targeted as a therapeutic approach to promote the accumulation of MDM with elevated MPO, by reprogramming progenitor cells systemically.
Methods
To elucidate the effects of progenitor reprogramming on changes in the macrophage compartment, stimulants of myelopoiesis were administered. Bone marrow, blood, and spleen were characterized using flow cytometry. Furthermore, utilizing genetic and transplantable mouse models of glioblastoma (RCAS PDGFB-ink4a model and the GL261 model), durable reprogramming was induced, and tumor progression was assessed using MRI.
Results
In tumor-bearing and non-tumor-bearing mice, myelopoiesis was successfully reprogrammed as depicted in blood by increased proportions of Ly6C+ monocytes expressing high levels of TNF-α, IL-10, MPO, and CCR2. Similar changes were observed in the spleens of non-tumor-bearing mice. Studies using mouse models of glioblastoma indicated changes in survival and tumor volumes following progenitor reprogramming.
Conclusions
Systemic reprogramming of the myeloid compartment could have beneficial effects in preclinical models of glioblastoma.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Canadian Institutes of Health Research (CIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract